by Ellie Lampton | Jun 29, 2026
Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to Humira BELLEVUE, Wash.—June 29, 2026—Researchers from Truveta have found that adoption of adalimumab biosimilars...
by Ellie Lampton | Jun 18, 2026
Analysis of nearly 154,000 adults identifies key factors associated with shingles vaccine uptake and completion BELLEVUE, Wash.—June 18, 2026—Researchers from Truveta have found that uptake of the shingles vaccine Shingrix has increased substantially among adults...
by Ellie Lampton | May 21, 2026
Most patients with newly identified heart failure did not receive repeat heart function assessment, despite guideline recommendations BELLEVUE, Wash.—May 21, 2026—A new peer-reviewed study led by Truveta and collaborators at Yale School of Medicine, Yale New Haven...
by Ellie Lampton | May 12, 2026
Combining one of the nation’s most comprehensive real-world clinical datasets with next-generation behavioral AI models to transform care delivery and patient outcomes BELLEVUE, Wash. and SAN FRANCISCO, Calif.—May 12, 2026—Truveta and Knit Health today announced a...
by Ellie Lampton | Apr 28, 2026
New AI-powered experience removes the time-to-evidence barrier, enabling healthcare leaders to better understand and make informed decisions based on what’s happening in care today BELLEVUE, Wash.—April 28, 2026— Truveta today announced Truveta Intelligence, a new...
